Deepti Pujare
Endocrinology, Diabetes & Metabolism · Los Gatos, CANPI 1639600125
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 5 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 4 manufacturers reported payments, led by BETA Bionics, Inc. at 45.8% of the total. Reporting peaked in 2024 at $286 and has fallen 57.3% since, to $122 in 2025. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in CA, where the typical reported total is $1,096.
Across 5 payments — averaging $107.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- BETA Bionics, Inc.$246
- Ascendis Pharma Endocrinology Inc$122
- Sanofi-aventis U.S. LLC$122
- Amgen$48
What the payments were for
- Food & beverage$538100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| BETA Bionics, Inc. | 2 | $246 |
| Ascendis Pharma Endocrinology Inc | 1 | $122 |
| Sanofi-aventis U.S. LLC | 1 | $122 |
| Amgen | 1 | $48 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iLet Bionic Pancreas$491
- TZIELD$122
- Yorvipath$122
How this compares
$538 in reported general payments places this provider in the 35th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 48 | $75,854 |
| MounjaroTirzepatide | 40 | $43,923 |
| OzempicSemaglutide | 18 | $29,406 |
| JanuviaSitagliptin Phosphate | 18 | $25,031 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 18 | $5,897 |
| Cinacalcet Hcl | 12 | $5,223 |
| Novolog FlexpenInsulin Aspart | 18 | $3,981 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 30 | $3,146 |
| Humalog Kwikpen U-100Insulin Lispro | 13 | $2,883 |
| Levothyroxine Sodium | 104 | $1,220 |
| SynthroidLevothyroxine Sodium | 12 | $978 |
| Alendronate Sodium | 74 | $736 |
| Glipizide | 41 | $617 |
| Metformin Hcl ErMetformin Hcl | 23 | $351 |
| Methimazole | 28 | $332 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Los Gatos
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Helen BaronRancho Mirage$958K
- Ken FujiokaSan Diego$747K
- Minou TranPico Rivera$663K
- James ChuMonterey$639K
- Anthony HeaneyLos Angeles$588K
- Daniel Einhornla Jolla$578K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.